EQ · Equillium, Inc.
$2.28
-0.04 (-1.72%)
At close · Jul 29
Market Cap
$146.69M
Shares
63.23M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$41.1M
0%
FY2025
Net Income
-$22.4M
-177.6%
FY2025
Operating Margin
-57.51%
-37.4pp
FY2025
Diluted EPS
-$0.39
-69.6%
FY2025
Operating Cash Flow
-$22.75M
-19.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| — | $41.1M | $41.1M | $36.08M | $15.76M | — | — | — | — | |
| $9.91M | $12.84M | $37.43M | $37.04M | $37.55M | $26.38M | $19.38M | $17.64M | $4.94M | |
| $10.46M | $10.79M | $11.94M | $13.57M | $17.24M | $11.41M | $10.16M | $9.09M | $3.67M | |
| — | — | — | — | $118K | $72K | $45K | $23K | $6102 | |
| $20.37M | $23.63M | $49.36M | $50.61M | $77.84M | $37.79M | $29.55M | $26.73M | $8.62M | |
| -$20.37M | -$23.63M | -$8.27M | -$14.52M | -$62.08M | -$37.79M | -$29.55M | -$26.73M | -$8.62M | |
| — | -57.51% | -20.12% | -40.24% | -393.91% | — | — | — | — | |
| — | — | — | — | -$61.96M | -$37.71M | -$29.5M | -$26.7M | -$8.61M | |
| $969K | $833K | $1.38M | $2.33M | $420K | $57K | $476K | $1.39M | $339.62K | |
| $1.6M | — | — | $1.77M | -$352K | -$1.27M | -$265K | $1.13M | -$4.63M | |
| — | -$22.4M | -$7.71M | -$12.76M | -$62.43M | -$39.05M | -$29.81M | -$25.6M | — | |
| — | $0 | $361K | $580K | $0 | $0 | — | — | — | |
| -$19.06M | -$22.4M | -$8.07M | -$13.34M | -$62.43M | -$39.05M | -$29.81M | -$25.6M | -$13.25M | |
| — | -54.5% | -19.63% | -36.96% | -396.14% | — | — | — | — | |
| -$19.42M | -$22.82M | -$7.43M | -$13.27M | -$62.21M | -$38.89M | -$30.13M | -$25.58M | -$13.25M | |
| USD/shares | — | -$0.39 | -$0.23 | -$0.38 | -$1.85 | — | — | — | — |
| USD/shares | — | -$0.39 | -$0.23 | -$0.38 | -$1.85 | — | — | — | — |
| shares | — | 57.3M | 35.36M | 34.73M | 33.73M | 28.81M | 20.36M | 17.38M | 12.19M |
| shares | — | 57.3M | 35.36M | 34.73M | 33.73M | 28.81M | 20.36M | 17.38M | 12.19M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $520K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.80×
EV/EBIT
—
Peer median 26.45×
P/E (TTM)
—
Peer median 4.43×
Peer medians compare against the 296 similar-size Biotechnology companies (of 522 listed).